Literature DB >> 9575340

Central IL-1 differentially regulates peripheral IL-6 and TNF synthesis.

H Kitamura1, S Okamoto, Y Shimamoto, M Morimatsu, A Terao, M Saito.   

Abstract

Centrally given interleukin (IL)-1 is known to induce a rapid rises in blood IL-6. To extend this and to examine the mechanism by which this occurs, the effects of intracerebroventricular (i.c.v.) injection of human recombinant IL-1 beta on mRNA expression of IL-6 and tumour necrosis factor (TNF) in the spleen and liver were examined in rats. I.c.v. injection of IL-1 produced a rapid rise of the tissue mRNA levels of Il-6 and TNF in both organs, prior to and/or in parallel with an increase in their serum levels. Pretreatment with chlorisondamine, a ganglionic blocking agent, inhibited the Il-6 responses, while it had little influence on the TNF responses. The results suggest that brain IL-1 induces peripheral production of IL-6, but not of TNF, through autonomic nervous system activation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9575340     DOI: 10.1007/s000180050151

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  3 in total

1.  Central injection of nitric oxide synthase inhibitors increases peripheral interleukin-6 and serum amyloid A: involvement of adrenaline from adrenal medulla.

Authors:  D K Song; Y B Im; J S Jung; J J Yan; S O Huh; H W Suh; Y H Kim
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

2.  Interleukin-1beta-induced promatrilysin expression is mediated by NFkappaB-regulated synthesis of interleukin-6 in the prostate carcinoma cell line, LNCaP.

Authors:  M S Maliner-Stratton; R D Klein; T S Udayakumar; R B Nagle; G T Bowden
Journal:  Neoplasia       Date:  2001 Nov-Dec       Impact factor: 5.715

Review 3.  Inflammation and neural signaling: etiologic mechanisms of the cancer treatment-related symptom cluster.

Authors:  Lisa J Wood; Kristianna Weymann
Journal:  Curr Opin Support Palliat Care       Date:  2013-03       Impact factor: 2.302

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.